Were economic evaluations well reported for the newly listed oncology drugs in China's national reimbursement drug list

• Autores principales: Liu Liu (Autor), Zhixin Jiang (Autor), Fuming Li (Autor), Yan Wei (Autor), Jian Ming (Autor), Yi Yang (Autor), Shimeng Liu (Autor), Lizheng Shi (Autor), Yingyao Chen (Autor)
• Formato: Libro
• Publicado: BMC, 2022-12-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Purpose To assess the reporting quality of published economic evaluations of the negotiated oncology drugs listed for China's 2020 National Reimbursement Drug List (NRDL). Methods A comprehensive search was conducted to identify economic evaluation studies of negotiated oncology drugs...